As of 2025-07-20, the Intrinsic Value of FUREN Group Pharmaceutical Co Ltd (600781.SS) is (138.96) CNY. This 600781.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.77 CNY, the upside of FUREN Group Pharmaceutical Co Ltd is -18,147.30%.
The range of the Intrinsic Value is (567.24) - (84.71) CNY
Based on its market price of 0.77 CNY and our intrinsic valuation, FUREN Group Pharmaceutical Co Ltd (600781.SS) is overvalued by 18,147.30%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (567.24) - (84.71) | (138.96) | -18147.3% |
| DCF (Growth 10y) | (84.88) - (514.98) | (133.51) | -17438.5% |
| DCF (EBITDA 5y) | (50.64) - (79.03) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (56.51) - (84.13) | (1,234.50) | -123450.0% |
| Fair Value | -21.96 - -21.96 | -21.96 | -2,952.01% |
| P/E | (80.73) - (79.15) | (76.42) | -10025.0% |
| EV/EBITDA | (44.15) - (43.28) | (52.78) | -6954.4% |
| EPV | (38.15) - (47.11) | (42.63) | -5636.8% |
| DDM - Stable | (10.49) - (51.10) | (30.79) | -4099.1% |
| DDM - Multi | (7.36) - (36.76) | (13.17) | -1810.5% |
| Market Cap (mil) | 482.91 |
| Beta | 0.60 |
| Outstanding shares (mil) | 627.16 |
| Enterprise Value (mil) | 4,850.13 |
| Market risk premium | 6.13% |
| Cost of Equity | 22.52% |
| Cost of Debt | 5.00% |
| WACC | 6.31% |